Skip to main content




Drop in COVID-19 vaccine efficacy against Delta seen in US nursing homes

Drop in COVID-19 vaccine efficacy against Delta seen in US nursing homes

A syringe is filled with a dose of Pfizer's COVID-19 vaccine at a pop-up community vaccination centre at the Gateway World Christian Center in Valley Stream, New York, on Feb 23, 2021. (Photo: REUTERS/Brendan McDermid)

WASHINGTON: The effectiveness of COVID-19 vaccines for people in American nursing homes and long-term care facilities, where residents are often elderly and frail, has dropped since the Delta variant became dominant in the United States, government researchers said on Wednesday (Aug 18).

Despite this decline, the vaccines are still highly effective at preventing illness severe enough to require hospitalisation, according to research published in the US Centers for Disease Control and Prevention's (CDC) Morbidity and Mortality Weekly Report.

The spread of the highly infectious Delta variant, which according to CDC data accounted last month for more than 80 per cent of new US infections, has complicated efforts to combat the pandemic in the United States and globally.

CDC researchers compared weekly data from 3,862 nursing homes and long-term care facilities spanning Mar 1 to May 9, before Delta became widespread, to data from 14,917 such facilities covering Jun 21 to Aug 9, when the variant was responsible for the majority of new infections.

They found that efficacy of the two-dose vaccines from Pfizer-BioNTech and Moderna for preventing any coronavirus infection - mild or severe - dropped from 74.7 per cent to 53.1 per cent. Effectiveness estimates were similar for the Pfizer-BioNTech and Moderna vaccines, they said.

President Joe Biden's administration will require nursing home staff to be vaccinated against COVID-19 as a condition of participating in the Medicare and Medicaid government healthcare programs, the White House said on Wednesday.

The new study's findings were cited by federal health officials on Wednesday in their announcement that COVID-19 booster shots would be made widely available to Americans beginning on Sep 20, with protection from initial vaccination waning over time.

The first groups to receive those boosters will include nursing home residents and other elderly Americans, as well as people with weak immune systems.

"Because the Delta variant became prominent in the United States within six months after the initial vaccine rollout to nursing home residents, we could not determine if the lower vaccine effectiveness seen in June-July in this study was due to potential waning immunity, reduced protection against the Delta variant, or a combination of both factors," CDC epidemiologist Dr Srinivas Nanduri said.

In a second study, New York State Department of Health officials found that by late July, 65 per cent of New York adults had been fully vaccinated with two doses of the Pfizer-BioNTech or Moderna shots or one dose of the Johnson & Johnson shot.

Between early May and late July, the vaccines' effectiveness for preventing new infections dropped from 91.7 per cent to 79.8 per cent, the study found. Vaccine efficacy at preventing hospitalisation held steady, ranging from 91.9 per cent to 95.3 per cent, it found.

The effectiveness of the two-dose vaccines against hospitalisation lasts at least six months, according to a separate study by researchers in 18 US states who reviewed data from 3,089 hospitalised patients, including 1,194 with COVID-19.

Vaccine efficacy against COVID-19-associated hospitalisation was 86 per cent between two and 12 weeks from receipt of the second vaccine dose, they found. It was 84 per cent between 13 and 24 weeks, with no significant change between these periods, they found. Over the full six months, they found, it was 90 per cent among adults without immunocompromising conditions.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:


Source: Reuters/ec


Also worth reading